HT
ARCT icon

Headlands Technologies’s Arcturus Therapeutics ARCT Stock Holding History

Headlands Technologies’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,095
Closed -$60.1K – 915
2023
Q2 		$60.1K Buy
+2,095
New +$57K 0.02% 449

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Headlands Technologies's ARCT Position: Q3 2023 in Review

Headlands Technologies sold out of Arcturus Therapeutics (ARCT) in Q3 2023, closing a stake of 2,095 shares — an estimated $60.1K sold.

Headlands Technologies first reported a position in ARCT in Q2 2023 and held it in 1 quarter. The position peaked at $60.1K in Q2 2023. 145 funds tracked by Wall St. Rank hold ARCT as of Q3 2023.

  • Headlands Technologies reported no remaining Arcturus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Headlands Technologies sold 2,095 Arcturus Therapeutics shares in Q3 2023, an estimated $60.1K.
  • Headlands Technologies first reported a position in Arcturus Therapeutics in Q2 2023 and held it in 1 quarter.
  • Headlands Technologies's Arcturus Therapeutics position peaked at $60.1K in Q2 2023.
  • 145 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2023.

Based on Headlands Technologies's 13F filing for Q3 2023, filed 9 Nov 2023.